Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
J Infect
    May 2025
  1. PETER RS, Sedelmaier L, Nieters A, Brockmann SO, et al
    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study.
    J Infect. 2025;90:106500.
    >> Share

  2. HOOG M, Westrhenen ESH, Winkel AM, Jong MD, et al
    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts.
    J Infect. 2025 May 9:106501. doi: 10.1016/j.jinf.2025.106501.
    >> Share

  3. GAO Y, Zhang J, Liu M, Bu Q, et al
    Superior antiviral efficacy of combined 3CL protease and RdRp inhibition compared to 3CL protease inhibitor monotherapy in hospitalized COVID-19 patients.
    J Infect. 2025;90:106502.
    >> Share

    April 2025
  4. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    >> Share

  5. OVERTON CE, Fyles M, Mellor J, Paton RS, et al
    SARS-CoV-2 test sensitivity and duration of positivity in the UK during the 2023/2024 Winter: A prospective cohort study based on self-reported data.
    J Infect. 2025;90:106485.
    >> Share

  6. DAHL TB, Aftab F, Prebensen C, Berdal JE, et al
    Imidazole propionate is increased in severe COVID-19 and correlates with cardiac involvement.
    J Infect. 2025;90:106494.
    >> Share

  7. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    >> Share

    March 2025
  8. BING J, Huang Y, Du H, Guo P, et al
    Rapid spread of Candida auris in China after COVID-19.
    J Infect. 2025 Mar 21:106476. doi: 10.1016/j.jinf.2025.106476.
    >> Share

  9. CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al
    Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands.
    J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474.
    >> Share

  10. JIN R, Qin T, Li P, Yuan J, et al
    Increased Circulation of Adenovirus in China During 2023-2024: Association with an Increased Prevalence of Species B and School-Associated Transmission.
    J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475.
    >> Share

  11. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
    Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
    J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
    >> Share

  12. WARD T, Paton RS, Overton CE, Mellor J, et al
    Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey.
    J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461.
    >> Share

    February 2025
  13. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
    J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
    >> Share

  14. AO G, Li T, Wang Y, Balzer N, et al
    The effect of amubarvimab-romlusevimab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2025;90:106442.
    >> Share

  15. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    >> Share

    January 2025
  16. QUINT JK, Dube S, Carty L, Yokota R, et al
    Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.
    J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432.
    >> Share

  17. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    >> Share

  18. ZSIGMOND B, Trecchi N, Ladhani SN, Doerholt K, et al
    Early outpatient treatment of SARS-COV-2 infection in non-hospitalised high-risk paediatric patients in London, UK.
    J Infect. 2025;90:106425.
    >> Share

  19. SILVA SOUZA M, Pires Farias J, de Souza Ferreira LC, Amorim JH, et al
    Declining COVID-19 vaccination coverage in Brazil: A global health warning.
    J Infect. 2025;90:106418.
    >> Share

  20. FENG S, Bibi S, Aley PK, Cappuccini F, et al
    Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
    J Infect. 2025;90:106423.
    >> Share

  21. ROMERO-RAMIREZ A, Somasundaran A, Kontogianni K, Parkes J, et al
    Evaluation of the diagnostic accuracy of Xpert(R) Mpox and STANDARD M10 MPX/OPX for the detection of monkeypox virus.
    J Infect. 2025 Jan 15:106413. doi: 10.1016/j.jinf.2025.106413.
    >> Share

  22. WENDEL-GARCIA PD, Ceccato A, Motos A, Franch-Llasat D, et al
    Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study.
    J Infect. 2025 Jan 13:106411. doi: 10.1016/j.jinf.2025.106411.
    >> Share

  23. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    >> Share

  24. NURMI V, Mayne R, Knight C, Almonacid-Mendoza HL, et al
    Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.
    J Infect. 2025 Jan 9:106412. doi: 10.1016/j.jinf.2025.106412.
    >> Share

  25. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    >> Share

  26. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    >> Share

    December 2024
  27. RUBIO R, Yavlinsky A, Zamudio ME, Molinos-Albert LM, et al
    Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
    J Infect. 2024 Dec 31:106402. doi: 10.1016/j.jinf.2024.106402.
    >> Share

  28. MENSAH AA, Stowe J, Brown K, LopezBernal J, et al
    COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes in England.
    J Infect. 2024 Dec 27:106392. doi: 10.1016/j.jinf.2024.106392.
    >> Share

  29. MONK EJM, Foulkes S, Munro K, Atti A, et al
    Characterisation of the SARS-CoV-2 pandemic in healthcare workers within the United Kingdom: risk factors for infection during four successive waves.
    J Infect. 2024 Dec 27:106393. doi: 10.1016/j.jinf.2024.106393.
    >> Share

  30. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    >> Share

    November 2024
  31. PENG Y, Shen H, Zhang Y, Zeng S, et al
    A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
    J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
    >> Share

  32. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    >> Share

  33. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    >> Share

  34. REN Z, Yang M, Su G, Qian G, et al
    Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study.
    J Infect. 2024 Nov 17:106355. doi: 10.1016/j.jinf.2024.106355.
    >> Share

  35. SEPULVEDA N, Westermeier F
    On the prevalence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome after a SARS-CoV-2 infection.
    J Infect. 2024;89:106353.
    >> Share

  36. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    >> Share

  37. FOONG KS
    Corrigendum to "The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19" [J Infe
    J Infect. 2024;89:106343.
    >> Share

  38. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    >> Share

  39. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    >> Share

  40. HO A, McInnes N, Blunsum A, Quinn J, et al
    Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
    J Infect. 2024;89:106338.
    >> Share

    October 2024
  41. WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    >> Share

  42. KUMAR NP, Balaji S, Devi PG, Ramraj B, et al
    Inflammatory Cytokine Responses in Pediatric tuberculosis with or without SARS-CoV-2 seropositivity.
    J Infect. 2024 Oct 17:106314. doi: 10.1016/j.jinf.2024.106314.
    >> Share

  43. WEI X, Wang L, Li M, Qi J, et al
    Novel imported clades accelerated the RSV surge in Beijing, China, 2023-2024.
    J Infect. 2024 Oct 17:106321. doi: 10.1016/j.jinf.2024.106321.
    >> Share

  44. MEIRMAN TD, Shapira B, Balicer RD, Rokach L, et al
    Trends of Common Laboratory Biomarkers after SARS-CoV-2 Infection.
    J Infect. 2024 Oct 16:106318. doi: 10.1016/j.jinf.2024.106318.
    >> Share

  45. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    >> Share

  46. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    >> Share

  47. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    >> Share

  48. LI Y, Zhang X, Yi J, Chen Y, et al
    Synergistic evolution: the dynamic adaptation of SARS-CoV-2 and human protective immunity in the real world.
    J Infect. 2024 Oct 9:106310. doi: 10.1016/j.jinf.2024.106310.
    >> Share

  49. MUSCATELLO DJ, Rose N, Paul KK, Ware S, et al
    Epidemiological comparison of emergency department presentations with seasonal influenza or COVID-19 and an outcome of intensive care admission or death: a population-based records linkage study in New South Wales, Australia.
    J Infect. 2024 Oct 8:106307. doi: 10.1016/j.jinf.2024.106307.
    >> Share

  50. AMARILLA-IRUSTA A, Zenarruzabeitia O, Sevilla A, Sanda V, et al
    CD151 identifies a NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.
    J Infect. 2024 Oct 5:106304. doi: 10.1016/j.jinf.2024.106304.
    >> Share

  51. FYLES M, Overton CE, Ward T, Bennett E, et al
    Modelling multiplex testing for outbreak control.
    J Infect. 2024 Oct 1:106303. doi: 10.1016/j.jinf.2024.106303.
    >> Share

    September 2024
  52. AKSU MD, van der Ent T, Zhang Z, Riza AL, et al
    Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.
    J Infect. 2024 Sep 30:106300. doi: 10.1016/j.jinf.2024.106300.
    >> Share

  53. DEHLIA A, Guthridge MA
    The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2024 Sep 29:106297. doi: 10.1016/j.jinf.2024.106297.
    >> Share

  54. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    >> Share

  55. KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al
    Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.
    J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293.
    >> Share

  56. MAZZOTTA V, Mazzaferri F, Lanini S, Mirandola M, et al
    Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    J Infect. 2024 Sep 27:106294. doi: 10.1016/j.jinf.2024.106294.
    >> Share

  57. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    >> Share

  58. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    >> Share

  59. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    >> Share

  60. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    >> Share

  61. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    >> Share

  62. MCDONALD E, Pittet LF, Barry SE, Bonten M, et al
    Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: insights from prospectively collected data in the BRACE trial.
    J Infect. 2024 Sep 6:106267. doi: 10.1016/j.jinf.2024.106267.
    >> Share

  63. CHAPMAN ME, Brendish NJ, Morris M, Spalluto CM, et al
    Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: results of a prospective trial (ED-POC).
    J Infect. 2024 Sep 5:106264. doi: 10.1016/j.jinf.2024.106264.
    >> Share

    August 2024
  64. AZIZ AB, Sugimoto JD, Hong SL, You YA, et al
    Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.
    J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260.
    >> Share

  65. GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al
    Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study.
    J Infect. 2024;89:106261.
    >> Share

  66. HASAN T, Zhu NJ, Pearson C, Aylin P, et al
    Increased 30-day all-cause mortality associated with Gram-negative bloodstream infections in England during the COVID-19 pandemic.
    J Infect. 2024 Aug 29:106256. doi: 10.1016/j.jinf.2024.106256.
    >> Share

  67. HOBBS FR, Gbinigie OA, Shanyinde M, Yu LM, et al
    Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Aug 29:106248. doi: 10.1016/j.jinf.2024.106248.
    >> Share

  68. FOULKES S, Evans J, Neill C, Bishop J, et al
    Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: a cross-sectional survey in the SIREN cohort.
    J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259.
    >> Share

  69. GOTTLIEB RL, Clement M, Cook P, Deveikis A, et al
    The IL-6 Hypothesis in COVID-19: A Phase 2, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Free IL-6 Sequestration by the Monoclonal Antibody Sirukumab in Severe and Critical COVID-19.
    J Infect. 2024 Aug 23:106241. doi: 10.1016/j.jinf.2024.106241.
    >> Share

  70. FRYER HA, Geers D, Gommers L, Zaeck LM, et al
    Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246.
    >> Share

  71. MESSINA NL, Pittet LF, McDonald E, Moore C, et al
    BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.
    J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245.
    >> Share

  72. WANG HI, Doran T, Crooks MG, Khunti K, et al
    Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.
    J Infect. 2024;89:106235.
    >> Share

  73. QUEK AML, Wang S, Teng O, Shunmuganathan B, et al
    Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.
    J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238.
    >> Share

  74. SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al
    Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.
    J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242.
    >> Share

  75. YANG C, Sun JY, Li XL, Cheng N, et al
    Emerging and re-emerging genotype 2c porcine epidemic diarrhoea virus with high pathogenicity in China.
    J Infect. 2024;89:106192.
    >> Share

    July 2024
  76. LI J, Zhang Y, Liu Z, Yang Z, et al
    Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies.
    J Infect. 2024;89:106233.
    >> Share

  77. BECHMAN K, Green A, Russell MD, Yang Z, et al
    The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19.
    J Infect. 2024 Jul 15:106227. doi: 10.1016/j.jinf.2024.106227.
    >> Share

  78. HU Y, Shi W, Meng Q, Yuan L, et al
    Detection of Bordetella spp. in children with pertussis-like illness from 2018 to 2024 in China.
    J Infect. 2024;89:106222.
    >> Share

  79. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    >> Share

  80. KADAMBARI S, Abdullahi F, Celma C, Ladhani S, et al
    Epidemiological trends in viral meningitis in England: prospective national surveillance, 2013-2023.
    J Infect. 2024 Jul 8:106223. doi: 10.1016/j.jinf.2024.106223.
    >> Share

  81. STARKE KR, Kaboth P, Rath N, Reissig D, et al
    Cardiovascular disease risk after a SARS-CoV-2 infection: a systematic review and meta-analysis.
    J Infect. 2024 Jul 4:106215. doi: 10.1016/j.jinf.2024.106215.
    >> Share

  82. HALME ALE, Laakkonen S, Rutanen J, Nevalainen OPO, et al
    Short- and long-term effects of imatinib in hospitalised COVID-19 patients: A randomised trial.
    J Infect. 2024 Jul 3:106217. doi: 10.1016/j.jinf.2024.106217.
    >> Share

    June 2024
  83. BOOM TT, de Hoog MLA, Westerhof I, Jaddoe V, et al
    Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic.
    J Infect. 2024 Jun 29:106218. doi: 10.1016/j.jinf.2024.106218.
    >> Share

  84. BOYS R, Plank J, Bird P, Fletcher O, et al
    Impact of COVID-19 restrictions on the incidence of respiratory viruses in two British Antarctic Survey bases.
    J Infect. 2024;89:106196.
    >> Share

  85. CHAKA A, Pan D, Irshad M, Piranie H, et al
    Inclusion of racial and ethnic groups in clinical trials for COVID-19 and post-acute COVID-19 syndrome: an analysis of studies registered on ClinicalTrials.gov.
    J Infect. 2024 Jun 20:106207. doi: 10.1016/j.jinf.2024.106207.
    >> Share

  86. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    >> Share

  87. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    >> Share

  88. LIU B, Xu L, Ma Y, Wang H, et al
    Evidence of immunity gap: Decline in antibodies against M. pneumoniae during the COVID-19 pandemic.
    J Infect. 2024 Jun 18:106209. doi: 10.1016/j.jinf.2024.106209.
    >> Share

  89. KAJIHARA T, Yahara K, Kamigaki T, Hirabayashi A, et al
    Effects of coronavirus disease 2019 on the spread of respiratory-transmitted human-to-human bacteria.
    J Infect. 2024 Jun 17:106201. doi: 10.1016/j.jinf.2024.106201.
    >> Share

  90. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    >> Share

  91. AUDRAN R, Karoui O, Donnet L, Soumas V, et al
    Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    J Infect. 2024 Jun 17:106205. doi: 10.1016/j.jinf.2024.106205.
    >> Share

  92. JIANG J, Li Y, Jiang Q, Jiang Y, et al
    Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis.
    J Infect. 2024 Jun 2:106190. doi: 10.1016/j.jinf.2024.106190.
    >> Share

  93. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.
    >> Share

    May 2024
  94. HAN B, Li XM, Li R, Ning W, et al
    Epidemiological Surveillance of Acute Respiratory Infections Based on Targeted Metagenomic Next Generation Sequencing During the Flu Season after COVID-19 Pandemic in Beijing.
    J Infect. 2024 May 22:106188. doi: 10.1016/j.jinf.2024.106188.
    >> Share

  95. YANG X, Li X, Qiu S, Liu C, et al
    Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: a systematic review and meta-analysis of aggregated participant data.
    J Infect. 2024 May 14:106183. doi: 10.1016/j.jinf.2024.106183.
    >> Share

  96. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.
    >> Share

  97. PANG CWK, Vale R, Lao KS, Khan AT, et al
    Increased Incidence of Invasive Pneumococcal Disease in Hong Kong in 2023.
    J Infect. 2024 May 11:106178. doi: 10.1016/j.jinf.2024.106178.
    >> Share

  98. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    >> Share

  99. HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al
    IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
    J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176.
    >> Share

    April 2024
  100. ZHOU J, Lan L, Ai S, Lin J, et al
    Corrigendum to: "People living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention" Journal of Infection, Volume 88, Issue 3, March 2024, 106122.
    J Infect. 2024 Apr 24:106157. doi: 10.1016/j.jinf.2024.106157.
    >> Share

  101. CHUN JY, Jeong SJ, Kim S, Choi S, et al
    Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary Aspergillosis using Non-invasive Proximal Airway Samples.
    J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159.
    >> Share

  102. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    >> Share

  103. COLSON P, Chaudet H, Delerce J, Pontarotti P, et al
    Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
    J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150.
    >> Share

    March 2024
  104. NG M, S D, L W, R B, et al
    Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
    J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
    >> Share

  105. GAYLIS NB, Yang OO
    Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) - The hunt for effective treatments.
    J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146.
    >> Share

  106. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    >> Share

  107. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    >> Share

  108. MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, de Mendoza C, et al
    COVID-19 Mortality Amongst the Immunosuppresed.
    J Infect. 2024 Mar 11:106137. doi: 10.1016/j.jinf.2024.106137.
    >> Share

  109. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    >> Share

  110. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    >> Share

    February 2024
  111. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    >> Share

  112. HAYWARD G, Yu LM, Little P, Gbinigie O, et al
    Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130.
    >> Share

  113. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    >> Share

  114. ZHOU J, Lan L, Ai S, Lin J, et al
    People Living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention.
    J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122.
    >> Share

  115. HITES M, Massonnaud CR, Jamard S, Goehringer F, et al
    Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial.
    J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120.
    >> Share

  116. YAO Z, Zhang L, Duan Y, Tang X, et al
    Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
    J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121.
    >> Share

  117. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.
    >> Share

  118. XIE L, Luo G, Yang Z, Wu WC, et al
    The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract.
    J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024.
    >> Share

  119. HUNG KC, Chen IW, Sun CK
    Pulmonary dysfunction severity may impact optimal dexamethasone dosing in patients with COVID-19.
    J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024.
    >> Share

    January 2024
  120. LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al
    Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.
    J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024.
    >> Share

  121. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    >> Share

  122. CORNISH EF, van der Meeren LE, van der Hoorn MP, Schoenmakers S, et al
    Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies.
    J Infect. 2024 Jan 11:S0163-4453(24)00020-3. doi: 10.1016/j.jinf.2024.
    >> Share

  123. ZHANG H, Zhou K, Peng F, Gao Z, et al
    Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency.
    J Infect. 2024 Jan 6:S0163-4453(23)00600-X. doi: 10.1016/j.jinf.2023.
    >> Share

    December 2023
  124. ZONG K, Yuan P, Wang R, Luo Q, et al
    Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection.
    J Infect. 2023 Dec 13:S0163-4453(23)00589-3. doi: 10.1016/j.jinf.2023.
    >> Share

  125. FERNANDEZ-DE-LAS-PENAS C, Notarte KI, Macasaet R, Velasco JV, et al
    Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2023 Dec 13:S0163-4453(23)00590-X. doi: 10.1016/j.jinf.2023.
    >> Share

  126. STRAHM C, Kahlert CR, Gusewell S, Vuichard-Gysin D, et al
    Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC) after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker cohort.
    J Infect. 2023 Dec 7:S0163-4453(23)00588-1. doi: 10.1016/j.jinf.2023.
    >> Share

  127. AO G, Li T, Nasr B, Wang Y, et al
    The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2023;87:e107-e109.
    >> Share

  128. LIU Y, Sun R, Zhang H, Huang J, et al
    Trends and predictions of tuberculosis notification in mainland China during and after the COVID-19 pandemic.
    J Infect. 2023;87:e100-e103.
    >> Share

    November 2023
  129. PHAN J, Eslick GD, Elliott EJ
    Demystifying the global outbreak of severe acute hepatitis of unknown aetiology in children: A systematic review and meta-analysis.
    J Infect. 2023 Nov 24:S0163-4453(23)00580-7. doi: 10.1016/j.jinf.2023.
    >> Share

  130. GRAU S, Vela JM, Gurt A, Barcelo-Vidal J, et al
    Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients.
    J Infect. 2023 Nov 20:S0163-4453(23)00562-5. doi: 10.1016/j.jinf.2023.
    >> Share

  131. DIEP AN, Schyns J, Gourzones C, Goffin E, et al
    How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: an 18-month longitudinal study.
    J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023.
    >> Share

  132. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    >> Share

  133. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis - A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.
    >> Share

  134. HALL VJ, Insalata F, Foulkes S, Kirwan P, et al
    Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.
    >> Share

  135. LUNT R, Quinot C, Kirsebom F, Andrews N, et al
    The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
    J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.
    >> Share

    October 2023
  136. BRUHN M, Obara M, Chiyyeadu A, Costa B, et al
    Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.
    J Infect. 2023 Oct 30:S0163-4453(23)00551-0. doi: 10.1016/j.jinf.2023.
    >> Share

  137. JIANG W, Xu L, Wang Y, Hao C, et al
    Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic.
    J Infect. 2023 Oct 29:S0163-4453(23)00550-9. doi: 10.1016/j.jinf.2023.
    >> Share

  138. JIN Z, Wu J, Wang Y, Huang T, et al
    Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.
    >> Share

  139. HA L, Levian C, Greene N, Goldfarb I, et al
    Association between acceptance of routine pregnancy vaccinations and COVID-19 vaccine uptake in pregnant patients.
    J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023.
    >> Share

  140. MARJANEH MM, Challenger JD, Salas A, Gomez-Carballa A, et al
    Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
    J Infect. 2023 Oct 18:S0163-4453(23)00540-6. doi: 10.1016/j.jinf.2023.
    >> Share

  141. FENWICK C, Turelli P, Duhoo Y, Lau K, et al
    Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
    J Infect. 2023 Oct 16:S0163-4453(23)00539-X. doi: 10.1016/j.jinf.2023.
    >> Share

  142. BEARD KR, Borca F, Phan H, Brown E, et al
    Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory viruses within an acute oncology service improves patient care.
    J Infect. 2023 Oct 4:S0163-4453(23)00514-5. doi: 10.1016/j.jinf.2023.
    >> Share

  143. TIAN S, Liu T, Zhao XJ, Liu XL, et al
    Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.
    J Infect. 2023 Oct 4:S0163-4453(23)00515-7. doi: 10.1016/j.jinf.2023.
    >> Share

    September 2023
  144. VELLAS C, Latour J, Tremeaux P, Ranger N, et al
    Molecular Evolution of Omicron Variant in Immunocompromised Individuals with Chronic SARS-CoV-2 Infection.
    J Infect. 2023 Sep 30:S0163-4453(23)00513-3. doi: 10.1016/j.jinf.2023.
    >> Share

  145. ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al
    SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study.
    J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023.
    >> Share

  146. GAO Y, Zhang Y, Mou K, Man S, et al
    Alterations in the outer retina and choroid in patients after COVID-19 infection.
    J Infect. 2023 Sep 27:S0163-4453(23)00512-1. doi: 10.1016/j.jinf.2023.
    >> Share

  147. YAMAMOTO S, Mizoue T, Konishi M, Oshiro Y, et al
    Kinetics and durability of nucleocapsid-specific antibodies after SARS-CoV-2 reinfection.
    J Infect. 2023 Sep 26:S0163-4453(23)00511-X. doi: 10.1016/j.jinf.2023.
    >> Share

  148. SNOW TAC, Arulkumaran N, Singer M, Choi SH, et al
    Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic review and meta-analysis.
    J Infect. 2023 Sep 25:S0163-4453(23)00510-8. doi: 10.1016/j.jinf.2023.
    >> Share

  149. MATSUO OM, Lindoso L, Sousa Marques HH, Polanczyk GV, et al
    Mental health among children and adolescents after SARS-CoV-2 infection: a prospective study in a tertiary university hospital.
    J Infect. 2023 Sep 20:S0163-4453(23)00507-8. doi: 10.1016/j.jinf.2023.
    >> Share

  150. ALPIZAR SA, Accini J, Anderson DC, Eysa B, et al
    Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial.
    J Infect. 2023 Sep 8:S0163-4453(23)00500-5. doi: 10.1016/j.jinf.2023.
    >> Share

  151. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    >> Share

  152. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection against Delta infection after vaccination: a nested case-control within the UK-based SIREN study.
    J Infect. 2023 Sep 7:S0163-4453(23)00380-8. doi: 10.1016/j.jinf.2023.
    >> Share

  153. AMANO M, Ichikawa Y, Matsumoto S, Matsushita S, et al
    Longitudinal analysis of neutralization in sera from HCWs receiving 2 doses of Omicron BA.4/5-adapted bivalent vaccine.
    J Infect. 2023 Sep 1:S0163-4453(23)00464-4. doi: 10.1016/j.jinf.2023.
    >> Share

  154. DOWELL AC, Tut G, Begum J, Bruton R, et al
    Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection.
    J Infect. 2023 Sep 1:S0163-4453(23)00465-6. doi: 10.1016/j.jinf.2023.
    >> Share

    August 2023
  155. GUAN X, Huang Q, Dong M, Li M, et al
    SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022.
    J Infect. 2023 Aug 29:S0163-4453(23)00462-0. doi: 10.1016/j.jinf.2023.
    >> Share

  156. SHARMA SN
    Did the Black Death Give Birth to the Healthcare Hero?
    J Infect. 2023 Aug 25:S0163-4453(23)00460-7. doi: 10.1016/j.jinf.2023.
    >> Share

  157. CARCAILLON-BENTATA L, Makovski TT, Alleaume C, Decio V, et al
    Post-Covid-19 condition: A comprehensive analysis of the World Health Organisation definition.
    J Infect. 2023 Aug 19:S0163-4453(23)00458-9. doi: 10.1016/j.jinf.2023.
    >> Share

  158. WHITAKER HJ, Tsang RS, Byford R, Aspden C, et al
    COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study.
    J Infect. 2023 Aug 12:S0163-4453(23)00456-5. doi: 10.1016/j.jinf.2023.
    >> Share

  159. WAGENHAUSER I, Mees J, Reusch J, Lam TT, et al
    Determinants of Influenza A Infection Rate in Post-COVID-19 Era.
    J Infect. 2023 Aug 9:S0163-4453(23)00455-3. doi: 10.1016/j.jinf.2023.
    >> Share

  160. FAUSTINI SE, Cook A, Hill H, Al-Taei S, et al
    Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
    J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023.
    >> Share

    July 2023
  161. SUN B, Gao F
    Investigation of escape mechanisms of SARS-CoV-2 Omicron sub-lineages and exploration of potential antibodies for XBB.1.
    J Infect. 2023 Jul 26:S0163-4453(23)00387-0. doi: 10.1016/j.jinf.2023.
    >> Share

  162. PIERANGELI A, Nenna R, Fracella M, Scagnolari C, et al
    Genetic diversity and its impact on disease severity in respiratory syncytial virus subtype-A and -B bronchiolitis before and after pandemic restrictions in Rome.
    J Infect. 2023 Jul 24:S0163-4453(23)00381-X. doi: 10.1016/j.jinf.2023.
    >> Share

  163. THEODOSIOU AA, Read RC
    Artificial Intelligence, Machine Learning and Deep Learning: Potential Resources for the Infection Clinician.
    J Infect. 2023 Jul 17:S0163-4453(23)00379-1. doi: 10.1016/j.jinf.2023.
    >> Share

  164. KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al
    Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023.
    >> Share

  165. FEELISCH M, Clark AD, Cumpstey AF, Santolini J, et al
    Long COVID: Potential role of the Reactive Species Interactome.
    J Infect. 2023 Jul 11:S0163-4453(23)00376-6. doi: 10.1016/j.jinf.2023.
    >> Share

  166. RISSMANN M, Veldhuis Kroeze EJB, Tielens AGM, Rockx B, et al
    Influence of a chronic Schistosoma mansoni infection on the outcomes of a SARS-CoV-2 infection in the hamster model.
    J Infect. 2023 Jul 5:S0163-4453(23)00374-2. doi: 10.1016/j.jinf.2023.
    >> Share

  167. BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al
    Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
    J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.
    >> Share

  168. TAUCHER C, Lazarus R, Dellago H, Maurer G, et al
    Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COM
    J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.
    >> Share

    June 2023
  169. VARASI I, Lai A, Fiaschi L, Bergna A, et al
    Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination.
    J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023.
    >> Share

  170. WU JY, Hsu WH, Tsai YW, Liu TH, et al
    The association between zinc deficiency, and clinical outcomes of COVID-19.
    J Infect. 2023 Jun 29:S0163-4453(23)00343-2. doi: 10.1016/j.jinf.2023.
    >> Share

  171. DOWELL AC, Waiblinger D, Wright J, Ladhani SN, et al
    Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children.
    J Infect. 2023 Jun 28:S0163-4453(23)00340-7. doi: 10.1016/j.jinf.2023.
    >> Share

  172. SU HC, Lai ZL, Chang YC, Cheng MY, et al
    Genomic characteristics of SARS-CoV-2 variants and their clinical impact on patients with COVID-19 in Taiwan.
    J Infect. 2023 Jun 27:S0163-4453(23)00341-9. doi: 10.1016/j.jinf.2023.
    >> Share

  173. KELLY E, Greenland M, de Whalley PCS, Aley PK, et al
    Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
    J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.
    >> Share

  174. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    AUTHORS' REPLY TO A COMMENTARY ON THE POTENTIAL IMPACT OF COVID-19 PASSPORTS TO EPIDEMIOLOGICAL SITUATION.
    J Infect. 2023 Jun 15:S0163-4453(23)00333-X. doi: 10.1016/j.jinf.2023.
    >> Share

  175. FALLET B, Foglierini M, Porret R, Alcaraz A, et al
    Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
    J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.
    >> Share

  176. BISHARAT N, Campisi-Pinto S
    Determinants of reinfection with SARS-CoV-2 Omicron variant.
    J Infect. 2023 Jun 9:S0163-4453(23)00325-0. doi: 10.1016/j.jinf.2023.
    >> Share

  177. CAI J, Ruan J, Lin Q, Ren T, et al
    China faces the challenge of influenza A virus, including H3N8, in the post-COVID-19 era.
    J Infect. 2023 Jun 7:S0163-4453(23)00324-9. doi: 10.1016/j.jinf.2023.
    >> Share

  178. MOHN KG, Bredholt G, Onyango TB, Brokstad KA, et al
    SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity.
    J Infect. 2023 Jun 7:S0163-4453(23)00302-X. doi: 10.1016/j.jinf.2023.
    >> Share

  179. PASCALL DJ, Vink E, Blacow R, Bulteel N, et al
    Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent.
    J Infect. 2023 Jun 1:S0163-4453(23)00297-9. doi: 10.1016/j.jinf.2023.
    >> Share

    May 2023
  180. LIU P, Cheng F, Su L, Ye Z, et al
    An outbreak of influenza A in Shanghai after ending the zero-COVID policy in February-March 2023.
    J Infect. 2023 May 27:S0163-4453(23)00301-8. doi: 10.1016/j.jinf.2023.
    >> Share

  181. NG RW, Sze RK, Chong KC, Zhao S, et al
    Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in an infection-naive Hong Kong population.
    J Infect. 2023 May 26:S0163-4453(23)00298-0. doi: 10.1016/j.jinf.2023.
    >> Share

  182. KANG SW, Kim JY, Park H, Lim SY, et al
    Corrigendum to "Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection" [J Infect 85 (2022) e69-e71].
    J Infect. 2023 May 25:S0163-4453(23)00294-3. doi: 10.1016/j.jinf.2023.
    >> Share

  183. FAVRESSE J, Cabo J, Douxfils J
    Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection.
    J Infect. 2023 May 19:S0163-4453(23)00292-X. doi: 10.1016/j.jinf.2023.
    >> Share

  184. DIAN Y, Meng Y, Sun Y, Deng G, et al
    Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.
    J Infect. 2023 May 17:S0163-4453(23)00290-6. doi: 10.1016/j.jinf.2023.
    >> Share

  185. NAOURI D, Pham T, Dres M, Vuagnat A, et al
    Differences in clinical characteristics and outcomes between COVID-19 and influenza in critically ill adult patients: a national database study.
    J Infect. 2023 May 16:S0163-4453(23)00289-X. doi: 10.1016/j.jinf.2023.
    >> Share

  186. ZHONG X, Pate A, Yang YT, Fahmi A, et al
    The impact of COVID -19 on antibiotic prescribing in primary care in England: evaluation and risk prediction of appropriateness of type and repeat prescribing.
    J Infect. 2023 May 12:S0163-4453(23)00288-8. doi: 10.1016/j.jinf.2023.
    >> Share

  187. PINANA M, Gonzalez-Sanchez A, Andres C, Abanto M, et al
    The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain.
    J Infect. 2023 May 11:S0163-4453(23)00262-1. doi: 10.1016/j.jinf.2023.
    >> Share

  188. LV W, He J, Shao J, Chen Y, et al
    Causal relationships between short-chain fatty acids and L-isoleucine biosynthesis and susceptibility and severity of COVID-19: Evidence from Mendelian randomization.
    J Infect. 2023 May 5:S0163-4453(23)00258-X. doi: 10.1016/j.jinf.2023.
    >> Share

  189. GAO M, Ao G, Hao X, Xie B, et al
    Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis.
    J Infect. 2023 May 3:S0163-4453(23)00256-6. doi: 10.1016/j.jinf.2023.
    >> Share

    April 2023
  190. XU J, Mao D, Liang P, Du P, et al
    Undetectable intrauterine transmission during the first trimester of pregnancy in woman after COVID-19 infection.
    J Infect. 2023 Apr 26:S0163-4453(23)00255-4. doi: 10.1016/j.jinf.2023.
    >> Share

  191. AWAN UA, Hussain M, Qureshi M, Siddique Z, et al
    From COVID-19 to Measles: Prioritizing Immunization in Pakistan's Far-Flung Regions.
    J Infect. 2023 Apr 26:S0163-4453(23)00253-0. doi: 10.1016/j.jinf.2023.
    >> Share

  192. ZHOU Y, Yan H, Zhou Q, Feng R, et al
    Impact of COVID-19 control measures on Legionella pneumophila infections in children in Henan, China.
    J Infect. 2023 Apr 26:S0163-4453(23)00254-2. doi: 10.1016/j.jinf.2023.
    >> Share

  193. AZIZ NA, Nash SG, Zaidi A, Nyberg T, et al
    Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.
    J Infect. 2023 Apr 24:S0163-4453(23)00249-9. doi: 10.1016/j.jinf.2023.
    >> Share

  194. FURUSE Y
    Estimation of excess cardiovascular deaths after COVID-19 in 2020.
    J Infect. 2023 Apr 24:S0163-4453(23)00251-7. doi: 10.1016/j.jinf.2023.
    >> Share

  195. LIU X, Munro APS, Wright A, Feng S, et al
    Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    J Infect. 2023 Apr 19:S0163-4453(23)00247-5. doi: 10.1016/j.jinf.2023.
    >> Share

  196. LUO J, Li A, Liu C, Wang Y, et al
    The effect of bebtelovimab on clinical outcomes in patients with COVID-19: a meta-analysis.
    J Infect. 2023 Apr 19:S0163-4453(23)00210-4. doi: 10.1016/j.jinf.2023.
    >> Share

  197. PIGHI L, Henry BM, De Nitto S, Salvagno GL, et al
    Cellular immunity against SARS-CoV-2 depends on the serological status.
    J Infect. 2023 Apr 13:S0163-4453(23)00203-7. doi: 10.1016/j.jinf.2023.
    >> Share

  198. TEYSSOU E, Marot S, Gothland A, Malet I, et al
    SARS-CoV-2 variant-dependent inflammasome activation.
    J Infect. 2023 Apr 13:S0163-4453(23)00205-0. doi: 10.1016/j.jinf.2023.
    >> Share

  199. LIU X, Munro AP, Feng S, Janani L, et al
    Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
    J Infect. 2023 Apr 11:S0163-4453(23)00198-6. doi: 10.1016/j.jinf.2023.
    >> Share

  200. MORRISON H, Perrin F, Dedicoat M, Ahmed R, et al
    Impact of COVID-19 on NHS Tuberculosis Services: Results of a UK-wide survey.
    J Infect. 2023 Apr 10:S0163-4453(23)00204-9. doi: 10.1016/j.jinf.2023.
    >> Share

  201. SHAW RH, Greenland M, Stuart AS, Aley PK, et al
    Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    J Infect. 2023 Apr 5:S0163-4453(23)00199-8. doi: 10.1016/j.jinf.2023.
    >> Share

  202. ZHAO D, Yi H, Dian Y, Meng Y, et al
    Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients.
    J Infect. 2023 Apr 3:S0163-4453(23)00200-1. doi: 10.1016/j.jinf.2023.
    >> Share

  203. CHEN H, Zhang L, Zhang Y, Chen G, et al
    Prevalence and clinical features of long COVID from omicron infection in children and adults.
    J Infect. 2023;86:e97-e99.
    >> Share

    March 2023
  204. GAO Y, Luo Z, Ren S, Duan Z, et al
    Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19.
    J Infect. 2023 Mar 30:S0163-4453(23)00192-5. doi: 10.1016/j.jinf.2023.
    >> Share

  205. KELLENI MT
    SARS CoV-2 Genetic Jump to a New SARS CoV-3 Pandemic: Let's Be Prepared.
    J Infect. 2023 Mar 21:S0163-4453(23)00147-0. doi: 10.1016/j.jinf.2023.
    >> Share

  206. NAMGUNG SH, Jung J, Kim SK, Kim EO, et al
    Incidence of tuberculosis infection in healthcare workers in high-risk departments for tuberculosis after universal wearing of KF94 mask during COVID-19 pandemic.
    J Infect. 2023 Mar 21:S0163-4453(23)00146-9. doi: 10.1016/j.jinf.2023.
    >> Share

  207. HSU WH, Shiau BW, Tsai YW, Wu JY, et al
    The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
    J Infect. 2023 Mar 21:S0163-4453(23)00145-7. doi: 10.1016/j.jinf.2023.
    >> Share

  208. DANIAL-FARRAN N, Khlaila M, Avraham-Kelbert M, Chazan B, et al
    Genetic Variant in Complement Receptor 1 (CR1, CD35) is Associated with A Cluster of Severe Fatal COVID-19 in a Family.
    J Infect. 2023 Mar 14:S0163-4453(23)00143-3. doi: 10.1016/j.jinf.2023.
    >> Share

  209. CLARK TW, Lindsley K, Wigmosta TB, Bhagat A, et al
    Rapid Multiplex PCR for Respiratory Viruses Reduces Time to Result and Improves Clinical Care: Results of a Systematic Review and Meta-Analysis.
    J Infect. 2023 Mar 9:S0163-4453(23)00134-2. doi: 10.1016/j.jinf.2023.
    >> Share

  210. GERETTI AM, Austin H, Villa G, Smith C, et al
    Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database.
    J Infect. 2023 Mar 9:S0163-4453(23)00130-5. doi: 10.1016/j.jinf.2023.
    >> Share

  211. BHAT S, Das L, Maheshwari D, Badal D, et al
    Effect of Calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial.
    J Infect. 2023 Mar 6:S0163-4453(23)00131-7. doi: 10.1016/j.jinf.2023.
    >> Share

  212. WANG H, Liu Y, Li P, Liu C, et al
    Emergence of epidemic variants of SARS-CoV-2 by acquiring combinations of new highly mutable nucleotides in its genome.
    J Infect. 2023 Mar 6:S0163-4453(23)00133-0. doi: 10.1016/j.jinf.2023.
    >> Share

  213. QUILES-JIMENEZ A, Sousa M, Huse C, Dyrhol-Riise AM, et al
    Severely-ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome.
    J Infect. 2023 Mar 6:S0163-4453(23)00132-9. doi: 10.1016/j.jinf.2023.
    >> Share

  214. LIU P, Xu J
    Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022 - January 2023.
    J Infect. 2023 Mar 1:S0163-4453(23)00127-5. doi: 10.1016/j.jinf.2023.
    >> Share

    February 2023
  215. SCARPA F, Imperia E, Azzena I, Giovanetti M, et al
    Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage.
    J Infect. 2023 Feb 28:S0163-4453(23)00126-3. doi: 10.1016/j.jinf.2023.
    >> Share

  216. SHAVA E, Izu A, Gaolathe T, Walker A, et al
    Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.
    J Infect. 2023 Feb 28:S0163-4453(23)00123-8. doi: 10.1016/j.jinf.2023.
    >> Share

  217. DENG Y, Han S, Liu J, Guo L, et al
    The risks of death and hospitalizations associated with SARS-CoV-2 Omicron declined after lifting testing and quarantining measures.
    J Infect. 2023 Feb 27:S0163-4453(23)00118-4. doi: 10.1016/j.jinf.2023.
    >> Share

  218. GUO H, Zhao T
    Multiple mutations of IFITM3 are associated with COVID-19 susceptibility.
    J Infect. 2023 Feb 23:S0163-4453(23)00120-2. doi: 10.1016/j.jinf.2023.
    >> Share

  219. ZHOU P, Gong F, Ji T, Cao C, et al
    Enriched CXCR3(+) CXCR5(+) CD8(+) T cells in SARS-CoV-2 infected and vaccinated individuals effectively respond to the antigen in recall.
    J Infect. 2023 Feb 23:S0163-4453(23)00109-3. doi: 10.1016/j.jinf.2023.
    >> Share

  220. UELAND T, Aikas LAO, Dahl TB, Gregersen I, et al
    Low-Density Lipoprotein Particles Carrying Proinflammatory Proteins with Altered Aggregation Pattern Detected in COVID-19 Patients 3 Months After HospitalizationRunning title: Low-Density Lipoprotein Particles in COVID-19 Patients.
    J Infect. 2023 Feb 21:S0163-4453(23)00111-1. doi: 10.1016/j.jinf.2023.
    >> Share

  221. ZHANG K, Chen R, Jiang Q
    Allopurinol Increased the Risk of COVID-19 Hospitalization Mediated by E-Selectin Downregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00116-0. doi: 10.1016/j.jinf.2023.
    >> Share

  222. PUTRI DU, Huang CK, Ou TY, Lin CF, et al
    Persistent dysregulation of cellular immunity following COVID-19 recovery despite minimal post-COVID-19 sequelae manifestationRunning title: Occult post-COVID immune dysregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00112-3. doi: 10.1016/j.jinf.2023.
    >> Share

  223. MEI R, Kwok SLL, Lau EHY, Lo THK, et al
    Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity.
    J Infect. 2023 Feb 21:S0163-4453(23)00113-5. doi: 10.1016/j.jinf.2023.
    >> Share

  224. WAN EYF, Wang B, Mathur S, Chan CIY, et al
    Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.
    J Infect. 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023.
    >> Share

  225. YANG F, Zhang N, Meng R, Wang K, et al
    Non-causal Association of COVID-19 with Systemic Lupus Erythematosus: Evidence from a Bidirectional Mendelian RandomizationRunning title: Association of COVID-19 with SLE.
    J Infect. 2023 Feb 21:S0163-4453(23)00115-9. doi: 10.1016/j.jinf.2023.
    >> Share

  226. VALENTINI D, Carfi A, Di Paola A, Yarci-Carrion A, et al
    Factor associated with SARS-CoV-2 vaccination serological efficacy in adolescents and adults with Down syndrome: data from an international, collaborative initiative of the Trisomy 21 Research SocietyRUNNING TITLE: Factors determining COVID-19 vaccine
    J Infect. 2023 Feb 20:S0163-4453(23)00090-7. doi: 10.1016/j.jinf.2023.
    >> Share

  227. POWELL AA, Ireland G, Leeson R, Lacey A, et al
    National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021.
    J Infect. 2023 Feb 15:S0163-4453(23)00085-3. doi: 10.1016/j.jinf.2023.
    >> Share

  228. BIRD PW, Pan D, Martin CA, Gogoi M, et al
    Awareness of HIV, Hepatitis B, Hepatitis C, Tuberculosis and COVID-19 in Migrant Students in the UK - A Pilot Survey from an Institute of Higher Education.
    J Infect. 2023 Feb 14:S0163-4453(23)00086-5. doi: 10.1016/j.jinf.2023.
    >> Share

  229. ZHANG W, Sun M, Zhang P, Liang Y, et al
    Epidemiological characteristics of Cytomegalovirus infection in children before and after the COVID-19 pandemic in Henan, China, 2016 - 2022.
    J Infect. 2023 Feb 10:S0163-4453(23)00081-6. doi: 10.1016/j.jinf.2023.
    >> Share

  230. MENG R, Zhang N, Yang F, Xu Z, et al
    Blood Transcriptome Analysis Revealed the Crosstalk Between Severe COVID-19 and Systemic Lupus Erythematosus.
    J Infect. 2023 Feb 10:S0163-4453(23)00080-4. doi: 10.1016/j.jinf.2023.
    >> Share

  231. LI L, Song X, Sun H, Ma J, et al
    Changes of pathogen distribution in children with wound infections before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2023 Feb 9:S0163-4453(23)00079-8. doi: 10.1016/j.jinf.2023.
    >> Share

  232. HSU WH, Tsai YW, Wu JY, Liu TH, et al
    Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors.
    J Infect. 2023 Feb 9:S0163-4453(23)00076-2. doi: 10.1016/j.jinf.2023.
    >> Share

  233. HU S, Zhang S, You Y, Tang J, et al
    Olfactory dysfunction after COVID-19; metanalysis reveals persistence in one third of patients six months after initial infection.
    J Infect. 2023 Feb 9:S0163-4453(23)00068-3. doi: 10.1016/j.jinf.2023.
    >> Share

  234. LI L, Jia R, Zhang Y, Sun H, et al
    Changes of parainfluenza virus infection in children before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2023 Feb 9:S0163-4453(23)00078-6. doi: 10.1016/j.jinf.2023.
    >> Share

  235. EVANS A, Qi C, Adebayo JO, Underwood J, et al
    Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
    J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.
    >> Share

  236. LI R, Wang M, Li D, Zhang Y, et al
    The impact of the COVID-19 pandemic on the number of hand, foot, and mouth disease due to enterovirus 71 infections.
    J Infect. 2023 Feb 8:S0163-4453(23)00075-0. doi: 10.1016/j.jinf.2023.
    >> Share

  237. CAILLARD S, Laugel E, Benotmane I, Kremer SF, et al
    Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding.
    J Infect. 2023 Feb 8:S0163-4453(23)00070-1. doi: 10.1016/j.jinf.2023.
    >> Share

  238. GRAY EJ, Nguyen-Van-Tam JS
    Molnupiravir for SARS-CoV-2 infection: Public health and policy implications.
    J Infect. 2023;86:121-122.
    >> Share

    January 2023
  239. AMANO M, Ichikawa Y, Uemura Y, Matsumoto S, et al
    Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.
    J Infect. 2023 Jan 31:S0163-4453(23)00066-X. doi: 10.1016/j.jinf.2023.
    >> Share

  240. LIANG J, Liu R, He W, Zeng Z, et al
    70% COVID-19 infection within three weeks in the population of Macao, China.
    J Infect. 2023 Jan 30:S0163-4453(23)00035-X. doi: 10.1016/j.jinf.2023.
    >> Share

  241. CHANG YH, Liu TH, Wu JY, Lai CC, et al
    The association between corticosteroids and aspergillosis among COVID-19 patients.
    J Infect. 2023 Jan 27:S0163-4453(23)00055-5. doi: 10.1016/j.jinf.2023.
    >> Share

  242. RANA MS, Usman M, Alam MM, Tahir M, et al
    The emergence of Mumps after the COVID-19 Pandemic in Pakistan: time to consider MMR vaccination strategies.
    J Infect. 2023 Jan 26:S0163-4453(23)00057-9. doi: 10.1016/j.jinf.2023.
    >> Share

  243. NISAR MI, Ansari N, Malik AA, Shahid S, et al
    Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative case-control study.
    J Infect. 2023 Jan 25:S0163-4453(23)00021-X. doi: 10.1016/j.jinf.2023.
    >> Share

  244. HANI E, Bertran M, Powell A, Williams H, et al
    Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron (B.1.1.529) infection in children and young people: active, prospective national surveillance, January-March 2022, England.
    J Infect. 2023 Jan 24:S0163-4453(23)00037-3. doi: 10.1016/j.jinf.2023.
    >> Share

  245. KELLENI MT
    Evolution of SARS CoV-2 Omicron Subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID Restrictions.
    J Infect. 2023 Jan 23:S0163-4453(23)00030-0. doi: 10.1016/j.jinf.2023.
    >> Share

  246. GENTRY CA, Nguyen P, Thind SK, Kurdgelashvili G, et al
    Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    J Infect. 2023 Jan 23:S0163-4453(23)00023-3. doi: 10.1016/j.jinf.2023.
    >> Share

  247. WU JY, Liu TH, Huang PY, Tsai YW, et al
    The effect of zinc on the outcome of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    J Infect. 2023 Jan 21:S0163-4453(23)00028-2. doi: 10.1016/j.jinf.2023.
    >> Share

  248. ZHAN H, Yang L, Liu Y, Li H, et al
    Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
    J Infect. 2023 Jan 21:S0163-4453(23)00034-8. doi: 10.1016/j.jinf.2023.
    >> Share

  249. LIANG Y, Hou L, Hou G, Zhang X, et al
    The influences of the COVID-19 pandemic on Epstein-Barr virus infection in children, Henan, China.
    J Infect. 2023 Jan 20:S0163-4453(23)00026-9. doi: 10.1016/j.jinf.2023.
    >> Share

  250. LIU X, Lv Z, Wang J, Zhou Y, et al
    IL1RA Mediated the Effects of Aspirin on Covid-19 severity: a Mendelian Randomization Study.
    J Infect. 2023 Jan 20:S0163-4453(23)00031-2. doi: 10.1016/j.jinf.2023.
    >> Share

  251. SALTO-ALEJANDRE S, Carretero-Ledesma M, Camacho-Martinez P, Berastegui-Cabrera J, et al
    Serum IFN-gamma and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients.
    J Infect. 2023 Jan 20:S0163-4453(23)00024-5. doi: 10.1016/j.jinf.2023.
    >> Share

  252. KANG SW, Kim JW, Kim JY, Lim SY, et al
    Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study.
    J Infect. 2023 Jan 19:S0163-4453(23)00029-4. doi: 10.1016/j.jinf.2023.
    >> Share

  253. RANA MS, Usman M, Alam MM, Tahir M, et al
    Changes in the prevalence of infectious diseases before and after the COVID-19 pandemic in Pakistan.
    J Infect. 2023 Jan 19:S0163-4453(23)00025-7. doi: 10.1016/j.jinf.2023.
    >> Share

  254. SHAH RA, Mentzer AJ, James T, Cox S, et al
    A novel near-patient host-protein score predicts COVID-19 deterioration at presentation to secondary care.
    J Infect. 2023 Jan 18:S0163-4453(23)00022-1. doi: 10.1016/j.jinf.2023.
    >> Share

  255. RU X, Chen S, Zhang T, Ding Z, et al
    Nonpharmaceutical intervention is an effective measure to block respiratory virus coinfections with SARS-CoV-2.
    J Infect. 2023 Jan 18:S0163-4453(23)00018-X. doi: 10.1016/j.jinf.2023.
    >> Share

  256. KANG SW, Park H, Kim JY, Lim SY, et al
    Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study.
    J Infect. 2023 Jan 18:S0163-4453(23)00020-8. doi: 10.1016/j.jinf.2023.
    >> Share

  257. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients.
    J Infect. 2023 Jan 14:S0163-4453(23)00017-8. doi: 10.1016/j.jinf.2023.
    >> Share

  258. LI X, Li T, Chen N, Kang P, et al
    Changes of Mycoplasma pneumoniae infection in children before and after COVID-19 pandemic in Henan, China.
    J Infect. 2023 Jan 13:S0163-4453(23)00012-9. doi: 10.1016/j.jinf.2022.
    >> Share

  259. TSAI YW, Tsai CF, Wu JY, Huang PY, et al
    The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: A retrospective cohort study from the TriNetX network.
    J Infect. 2023 Jan 9:S0163-4453(23)00007-5. doi: 10.1016/j.jinf.2023.
    >> Share

  260. DING X, Liang H, Qi X, Sun G, et al
    Changes of Klebsiella pneumoniae infection and carbapenem resistance in ICU elderly infected patients before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 9:S0163-4453(23)00009-9. doi: 10.1016/j.jinf.2023.
    >> Share

  261. XU J, Wang Y, Duan G, Liu F, et al
    Impact of non-pharmaceutical interventions during COVID-19 pandemic on measles and mumps in mainland China.
    J Infect. 2023 Jan 9:S0163-4453(23)00008-7. doi: 10.1016/j.jinf.2023.
    >> Share

  262. PATIL S, Chen H, Dong S, Liu S, et al
    Klebsiella pneumoniae infection in the paediatric population before and after the COVID-19 pandemic in Shenzhen, China.
    J Infect. 2023 Jan 8:S0163-4453(23)00004-X. doi: 10.1016/j.jinf.2023.
    >> Share

  263. LI Y, Liang H, Ding X, Cao Y, et al
    Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: A systematic review and meta-analysis.
    J Infect. 2023 Jan 6:S0163-4453(23)00001-4. doi: 10.1016/j.jinf.2023.
    >> Share

  264. YU Z, Xu S, Li L, Li M, et al
    Changes of Cytomegalovirus infection in neonates before and after the COVID19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 5:S0163-4453(23)00002-6. doi: 10.1016/j.jinf.2023.
    >> Share

  265. ZHAO S, Sha T, Xue Y, Chen H, et al
    Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19 Policy.
    J Infect. 2023 Jan 2:S0163-4453(22)00748-4. doi: 10.1016/j.jinf.2022.
    >> Share

  266. HIROTSU Y, Omata M
    Detection of the Omicron BA.2.75 subvariant in Japan.
    J Infect. 2023;86:e5-e7.
    >> Share

  267. CAMACHO J, Zulaica J, Gimenez E, Rusu L, et al
    Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naive individuals in the general population.
    J Infect. 2023 Jan 1:S0163-4453(22)00755-1. doi: 10.1016/j.jinf.2022.
    >> Share

    December 2022
  268. CILLONIZ C, Motos A, Castaneda T, Gabarrus A, et al
    Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study.
    J Infect. 2022 Dec 31:S0163-4453(22)00753-8. doi: 10.1016/j.jinf.2022.
    >> Share

  269. LIANG Y, Li J, Hou L, Zhang X, et al
    Changes of Staphylococcus aureus infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Dec 28:S0163-4453(22)00751-4. doi: 10.1016/j.jinf.2022.
    >> Share

  270. FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Diaz-Gil G, Gil-Crujera A, et al
    ACE1 rs1799752 Polymorphism is not Associated with Long-COVID Symptomatology in Previously Hospitalized COVID-19 Survivors.
    J Infect. 2022 Dec 27:S0163-4453(22)00752-6. doi: 10.1016/j.jinf.2022.
    >> Share

  271. LI Y, Cao Y, Ding X, Yang D, et al
    Influence of the COVID-19 pandemic on Staphylococcus aureus bloodstream infection in children, Henan, China.
    J Infect. 2022 Dec 25:S0163-4453(22)00746-0. doi: 10.1016/j.jinf.2022.
    >> Share

  272. SCHILDGEN O, Lusebrink J, Schildgen V
    Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning vaccine effectiveness is taking the easy way out.
    J Infect. 2022 Dec 24:S0163-4453(22)00744-7. doi: 10.1016/j.jinf.2022.
    >> Share

  273. KRONE M, Wagenhauser I, Knies K, Hofmann D, et al
    Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents.
    J Infect. 2022 Dec 21:S0163-4453(22)00740-X. doi: 10.1016/j.jinf.2022.
    >> Share

  274. JANKUNAS R, Sakalauskas L, Zamaryte-Sakaviciene K, Stakisaitis D, et al
    COMMENTARY ON THE IMPACT OF THE COVID-19 PASSPORTS IN LITHUANIA.
    J Infect. 2022 Dec 20:S0163-4453(22)00703-4. doi: 10.1016/j.jinf.2022.
    >> Share

  275. C O, H W, R B, E L, et al
    Following the Omicron wave, the majority of children in England have evidence of previous COVID infection.
    J Infect. 2022 Dec 18:S0163-4453(22)00701-0. doi: 10.1016/j.jinf.2022.
    >> Share

  276. LI X, Peng K, Cheng FW, Lam DC, et al
    Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
    J Infect. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022.
    >> Share

  277. LIANG Y, Zhang P, Du B, Zhang X, et al
    Changes of Mycoplasma pneumoniae infection in children before and after the COVID - 19 pandemic, Henan, China.
    J Infect. 2022 Dec 15:S0163-4453(22)00705-8. doi: 10.1016/j.jinf.2022.
    >> Share

  278. ZHANG M, Gao J, Guo Q, Zhang X, et al
    Changes of respiratory syncytial virus infection in children before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2022 Dec 15:S0163-4453(22)00702-2. doi: 10.1016/j.jinf.2022.
    >> Share

  279. LI L, Ma J, Guo P, Gao K, et al
    Changes of coagulase-negative Staphylococci infections in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 12:S0163-4453(22)00698-3. doi: 10.1016/j.jinf.2022.
    >> Share

  280. XU J, Wang Y, Liu F, Yang H, et al
    Changes of tuberculosis infection in mainland China before and after the COVID-19 pandemic.
    J Infect. 2022 Dec 11:S0163-4453(22)00699-5. doi: 10.1016/j.jinf.2022.
    >> Share

  281. KELLENI MT
    Real-life Practice of the Egyptian Kelleni's Protocol in the Current Tripledemic: COVID-19, RSV and Influenza.
    J Infect. 2022 Dec 10:S0163-4453(22)00697-1. doi: 10.1016/j.jinf.2022.
    >> Share

  282. CHENG P, Li L, Sun H, Zhu C, et al
    Changes of pathogen distribution in children with bacterial meningitis before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 10:S0163-4453(22)00696-X. doi: 10.1016/j.jinf.2022.
    >> Share

  283. HANNAWI S, Safeldin L, Abuquta A, Alamadi A, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Protein Booster Vaccine, SCTV01C in Adults Previously Vaccinated with Inactivated Vaccine: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Trial.
    J Infect. 2022 Dec 9:S0163-4453(22)00693-4. doi: 10.1016/j.jinf.2022.
    >> Share

  284. POZO-BALADO MDM, Ramos A, Rodriguez VG, Martinez IO, et al
    LONGITUDINAL AGE DIFFERENCES IN HUMORAL RESPONSES TO THE BNT162b2 VACCINE IN THE ELDERLY ARE LOST AFTER THE THIRD DOSE.
    J Infect. 2022 Dec 8:S0163-4453(22)00692-2. doi: 10.1016/j.jinf.2022.
    >> Share

  285. LIANG Y, Qin X, Hou G, Zhang X, et al
    Changes of Moraxella catarrhalis infection in children before and after the COVID-19 pandemic, Zhengzhou, China.
    J Infect. 2022 Dec 6:S0163-4453(22)00691-0. doi: 10.1016/j.jinf.2022.
    >> Share

  286. LI L, Yu Z, Li M, Sun H, et al
    Changes of Acinetobacter baumannii infections in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 2:S0163-4453(22)00689-2. doi: 10.1016/j.jinf.2022.
    >> Share

  287. LI K, Wang D, Qu H, Rui J, et al
    Viral Dynamics of Omicron BA.2.76 Variant of SARS-CoV-2 in a Cohort of COVID-19 Patients.
    J Infect. 2022 Dec 2:S0163-4453(22)00688-0. doi: 10.1016/j.jinf.2022.
    >> Share

  288. KAKIMOTO M, Miyamori D, Omori K, Kobayashi T, et al
    Impact of the early phase of COVID-19 on the trends of isolated bacteria in the national database of Japan: an interrupted time-series analysis.
    J Infect. 2022 Dec 1:S0163-4453(22)00686-7. doi: 10.1016/j.jinf.2022.
    >> Share

  289. CHEEMA HA, Shafiee A, Athar MMT, Shahid A, et al
    No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
    J Infect. 2022 Dec 1:S0163-4453(22)00683-1. doi: 10.1016/j.jinf.2022.
    >> Share

  290. JIANG L, Tang L, Zhu L, Zhu Y, et al
    Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic infectiousness.
    J Infect. 2022 Dec 1:S0163-4453(22)00687-9. doi: 10.1016/j.jinf.2022.
    >> Share

  291. ABDULJALIL JM, Elfiky AA
    Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective.
    J Infect. 2022;85:702-769.
    >> Share

    November 2022
  292. TANG Y, Dang X, Lv M, Norris SL, et al
    Changes in the prevalence of respiratory pathogens in children due to the COVID-19 pandemic: a systematic review and meta-analysis.
    J Infect. 2022 Nov 29:S0163-4453(22)00685-5. doi: 10.1016/j.jinf.2022.
    >> Share

  293. DENG YK, Shi KT, Liu Z, Zeng M, et al
    Persistent olfactory dysfunction 2 years after onset of COVID-19.
    J Infect. 2022 Nov 29:S0163-4453(22)00684-3. doi: 10.1016/j.jinf.2022.
    >> Share

  294. LV L, Li A, Jiang L, Zhang L, et al
    Deficiency of HTR4 and ADRB1 caused by SARS-CoV-2 spike may partially explain multiple COVID-19 related syndromes including depression, cognitive impairment, loss of appetite, heart failure, and hypertension.
    J Infect. 2022 Nov 28:S0163-4453(22)00682-X. doi: 10.1016/j.jinf.2022.
    >> Share

  295. CHEN D, Pan Y, Wang Y, Chen X, et al
    Serological response to COVID-19 vaccine and its predictors in patients with solid malignancies: a systematic review and meta-analysis of 16 cohort studies.
    J Infect. 2022 Nov 26:S0163-4453(22)00673-9. doi: 10.1016/j.jinf.2022.
    >> Share

  296. ZHENG M
    China plans to strike a balance between socio-economic development and anti-COVID-19 policy: report from the 20th National Congress of China.
    J Infect. 2022 Nov 25:S0163-4453(22)00680-6. doi: 10.1016/j.jinf.2022.
    >> Share

  297. TRKULJA V
    There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: a comment on two recent meta-analyses advocating its use.
    J Infect. 2022 Nov 24:S0163-4453(22)00677-6. doi: 10.1016/j.jinf.2022.
    >> Share

  298. LI L, Song C, Li P, Li Y, et al
    Changes of Escherichia coli infection in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Nov 24:S0163-4453(22)00678-8. doi: 10.1016/j.jinf.2022.
    >> Share

  299. ZHAO Y, Zhao Y, Zhou Y, Zhang Z, et al
    Inactivated COVID-19 vaccination and maternal renal function during early pregnancy: a retrospective cohort study of 6397 Chinese pregnant women.
    J Infect. 2022 Nov 22:S0163-4453(22)00676-4. doi: 10.1016/j.jinf.2022.
    >> Share

  300. YARCI-CARRION A, Esparcia-Pinedo L, Mateo-Jimenez G, Alfranca A, et al
    Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome.
    J Infect. 2022 Nov 20:S0163-4453(22)00675-2. doi: 10.1016/j.jinf.2022.
    >> Share

  301. WANG X, Sima L
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    J Infect. 2022 Nov 20:S0163-4453(22)00674-0. doi: 10.1016/j.jinf.2022.
    >> Share

  302. WANG G, Zhao K, Han J, Hu Z, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults: A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial.
    J Infect. 2022 Nov 17:S0163-4453(22)00649-1. doi: 10.1016/j.jinf.2022.
    >> Share

  303. ROMBAUTS A, Infante C, de Lagos MDAM, Alba J, et al
    Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study.
    J Infect. 2022 Nov 17:S0163-4453(22)00650-8. doi: 10.1016/j.jinf.2022.
    >> Share

  304. MARCEC R, Dodig VM, Likic R
    A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference.
    J Infect. 2022 Nov 17:S0163-4453(22)00672-7. doi: 10.1016/j.jinf.2022.
    >> Share

  305. HOQUE SA, Kotaki T, Pham NTK, Onda Y, et al
    Abundance of viral gastroenteritis before and after the emergence of COVID-19: Molecular evidence on wastewater.
    J Infect. 2022 Nov 17:S0163-4453(22)00648-X. doi: 10.1016/j.jinf.2022.
    >> Share

  306. LI T, Li X, Gao K, Dong G, et al
    Changes in pathogen distribution in the blood culture of neonates before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Nov 10. pii: S0163-4453(22)00644.
    >> Share

  307. HU S, You Y, Zhang S, Tang J, et al
    Multidrug-resistant infection in COVID-19 patients: a meta-analysis.
    J Infect. 2022 Nov 5. pii: S0163-4453(22)00640.
    >> Share

  308. MASHIMO Y, Yamazaki K, Kageyama T, Tanaka S, et al
    Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine.
    J Infect. 2022 Nov 2. pii: S0163-4453(22)00614.
    >> Share

  309. ZHANG N, Hu T, Zhang J, Mai W, et al
    Probable close contact transmission in a restaurant in China.
    J Infect. 2022;85:573-607.
    >> Share

  310. MARCEC R, Dodig VM, Likic R
    Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
    J Infect. 2022 Nov 1. pii: S0163-4453(22)00627.
    >> Share

    October 2022
  311. COSTA R, Signes-Costa J, Olea B, Tarraso J, et al
    Initial SARS-CoV-2 RNA load in nasopharyngeal specimens is not associated with severity and midterm resolution of pneumonia in COVID-19 patients.
    J Infect. 2022 Oct 28. pii: S0163-4453(22)00629.
    >> Share

  312. KANDEL C, Lee Y, Taylor M, Llanes A, et al
    Viral Dynamics of the SARS-CoV-2 Omicron Variant Among Household Contacts with 2 or 3 COVID-19 Vaccine Doses.
    J Infect. 2022 Oct 22. pii: S0163-4453(22)00625.
    >> Share

  313. NISHIKIMI A, Nakagawa T, Fujiwara M, Watanabe K, et al
    Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00621.
    >> Share

  314. GUO Y, Zhang Y, Hu Y
    COVID-19 subgroups may slow down biological age acceleration.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00616.
    >> Share

  315. ZHANG Y, Han S, Yao M, Guo X, et al
    Breakthrough Infection shapes humoral immunity against SARS-CoV-2 Omicron Variant.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00620.
    >> Share

  316. ASTURIAS EJ, Bai X, Bettinger JA, Borrow R, et al
    Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00623.
    >> Share

  317. SHINGLETON J, Williams H, Oligbu G, Powell A, et al
    The changing epidemiology of PIMS-TS across COVID-19 waves: prospective national surveillance, January 2021 to July 2022, England.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00617.
    >> Share

  318. ZHOU J, Zhao P, Nie M, Gao K, et al
    Changes of Haemophilus influenzae infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00615.
    >> Share

  319. ZHENG Q, Wang M, Cheng Y, Liu J, et al
    Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients.
    J Infect. 2022 Oct 17. pii: S0163-4453(22)00612.
    >> Share

  320. CHEEMA HA, Jafar U, Elrashedy AA, Shahid A, et al
    Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00608.
    >> Share

  321. WANG B, Yu Y, Yu Y, Wang N, et al
    Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China.
    J Infect. 2022 Oct 11. pii: S0163-4453(22)00466.
    >> Share

  322. LEE J, Park S, Kim JY, Lim SY, et al
    No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    J Infect. 2022 Oct 9. pii: S0163-4453(22)00600.
    >> Share

  323. ELFIKY AA, Ibrahim IM, Ibrahim MN, Elshemey WM, et al
    Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants.
    J Infect. 2022 Oct 8. pii: S0163-4453(22)00601.
    >> Share

  324. CAI H, Yan J, Wang J, Che X, et al
    Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19.
    J Infect. 2022 Oct 8. pii: S0163-4453(22)00562.
    >> Share

  325. RAFFERTY H, Cann A, Daunt A, Cooke GS, et al
    Changing patterns of clinical presentation of COVID-19 in hospital admissions: a single centre prospective cohort study.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00563.
    >> Share

  326. GREGERSEN I, Ueland T, Holter JC, Olsen MB, et al
    CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00559.
    >> Share

  327. BERTRAN M, Pereira SMP, Nugawela MD, Stephenson T, et al
    The relationship between Post COVID symptoms in young people and their parents.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00560.
    >> Share

    September 2022
  328. ZHENG Q, Ma P, Wang M, Chen Y, et al
    Efficacy and safety of Paxlovid for COVID-19:a meta-analysis.
    J Infect. 2022 Sep 30. pii: S0163-4453(22)00557.
    >> Share

  329. CHANDRA A, Hoeg TB
    Lack of correlation between school mask mandates and paediatric Covid-19 cases in a large cohort.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00550.
    >> Share

  330. LIU P, Xu J
    Resurgence of influenza virus activity during COVID-19 pandemic in Shanghai, China.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00555.
    >> Share

  331. LA Y, Hong JY, Lee HS, Lee EH, et al
    Increase of Multidrug-Resistant Bacteria After the COVID-19 Pandemic in South Korea: Time-series Analyses of a Long-term Multicenter Cohort.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00556.
    >> Share

  332. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.
    >> Share

  333. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.
    >> Share

  334. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.
    >> Share

  335. CHOI MJ, Choi JY, Hyun H, Nham E, et al
    Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: comparison between prior SARS-CoV-2-infected and infection-naive individuals.
    J Infect. 2022 Sep 23. pii: S0163-4453(22)00548.
    >> Share

  336. YAN F, Gao F
    RBD-ACE2 binding properties in five SARS-CoV-2 variants of concern with new perspectives in the design of pan-coronavirus peptide inhibitors.
    J Infect. 2022 Sep 14. pii: S0163-4453(22)00541.
    >> Share

  337. XU QY, Zheng XQ, Jia ZJ, Wu MJ, et al
    Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study.
    J Infect. 2022 Sep 12. pii: S0163-4453(22)00539.
    >> Share

  338. MOUSSAOUI ME, Desmecht S, Tashkeev A, Lambert N, et al
    Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naive people living with HIV.
    J Infect. 2022 Sep 9. pii: S0163-4453(22)00534.
    >> Share

  339. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study.
    J Infect. 2022 Sep 8. pii: S0163-4453(22)00535.
    >> Share

  340. WONG LSY, Loo EXL, Huang CH, Yap GC, et al
    Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies.
    J Infect. 2022 Sep 3. pii: S0163-4453(22)00515.
    >> Share

  341. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.
    >> Share

  342. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.
    >> Share

  343. PATAPNYAN E, Ronen O
    Parallel reduction in the prevalence of Bell's palsy, idiopathic sudden sensorineural hearing loss and viral infection diseases during the COVID-19 pandemic.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00518.
    >> Share

  344. COOPER DJ, Lear S, Watson L, Shaw A, et al
    A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00514.
    >> Share

  345. YIN Y, Lin J, Yuan S, Tong S, et al
    The relationship between early isolation and the duration of viral shedding of mild and asymptomatic infection with SARS-CoV-2 Omicron BA.2 variant.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00520.
    >> Share

    August 2022
  346. LAI CK, Lui GC, Wei Y, Chong KC, et al
    Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis.
    J Infect. 2022 Aug 31. pii: S0163-4453(22)00513.
    >> Share

  347. LINA L, Zhendong G, Sevalie S, Fangfang Z, et al
    Comparison of the amount of SARS-CoV-2 exhaled by Delta and Omicron patients.
    J Infect. 2022 Aug 28. pii: S0163-4453(22)00512.
    >> Share

  348. KIM SH, Kyu Cho H, Jeon CH, Sung Ock H, et al
    Diagnostic value of serum KL-6 and IL-6 levels in critically ill patients with COVID-19-associated pneumonia.
    J Infect. 2022 Aug 27. pii: S0163-4453(22)00477.
    >> Share

  349. WANG Y, Zheng J, Zhu K, Wang B, et al
    The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00506.
    >> Share

  350. GIDARI A, Schiaroli E, Sabbatini S, Bastianelli S, et al
    Impact of SARS-CoV-2 Omicron Variants on Serum Neutralization in a Cohort of Healthcare Workers Vaccinated with BNT162b2.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00507.
    >> Share

  351. BAYHAN GI, Korkmaz IO, Seyda E, Tekeli N, et al
    Are SARS-CoV-2 viral loads in children lower than in adults?
    J Infect. 2022 Aug 24. pii: S0163-4453(22)00509.
    >> Share

  352. LI K, Ruan F, Zhao Z, Guo Z, et al
    Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China.
    J Infect. 2022 Aug 22. pii: S0163-4453(22)00502.
    >> Share

  353. SUN YK, Xing JB, Xu ZY, Gao H, et al
    Re-emergence of Severe Acute Diarrhea Syndrome Coronavirus (SADS-CoV) in Guangxi, China, 2021.
    J Infect. 2022 Aug 21. pii: S0163-4453(22)00504.
    >> Share

  354. MIZOUE T, Yamamoto S, Konishi M, Oshiro Y, et al
    Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00480.
    >> Share

  355. WANG Y, Chen X, Xiao W, Zhao D, et al
    Rapid COVID-19 rebound in a severe COVID-9 patient during 20-day course of Paxlovid.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00478.
    >> Share

  356. NOLASCO S, Vitale F, Geremia A, Tramuto F, et al
    First case of monkeypox virus, SARS-CoV-2 and HIV co-infection.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00479.
    >> Share

  357. WAN EYF, Mok AHY, Yan VKC, Wang B, et al
    Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.
    J Infect. 2022 Aug 16. pii: S0163-4453(22)00472.
    >> Share

  358. GOMEZ-CARBALLA A, Martinon-Torres F, Salas A
    Is SARS-CoV-2 an oncogenic virus?
    J Infect. 2022 Aug 9. pii: S0163-4453(22)00469.
    >> Share

  359. CHANG YC, Hsiao CT, Chen WL, Su YD, et al
    BioFire FilmArray Respiratory Panel RP2.1 for SARS-CoV-2 detection: The pitfalls.
    J Infect. 2022 Aug 8. pii: S0163-4453(22)00468.
    >> Share

  360. AIELLO TF, Puerta-Alcalde P, Chumbita M, Monzo P, et al
    Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19.
    J Infect. 2022 Aug 5. pii: S0163-4453(22)00461.
    >> Share

  361. WU Y, Ma Z, Zhang Y, Zhang M, et al
    The role of cyclophilins in viral infec and the immune response.
    J Infect. 2022 Aug 4. pii: S0163-4453(22)00464.
    >> Share

  362. BASSETTI M, Zuccaro V, Asperges E, Scudeller L, et al
    Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, nonneutropenic, adult patients: an update including COVID-19 data.
    J Infect. 2022 Aug 4. pii: S0163-4453(22)00465.
    >> Share

  363. AO Y, Li J, Wei Z, Wang Z, et al
    Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China.
    J Infect. 2022 Aug 4. pii: S0163-4453(22)00462.
    >> Share

    July 2022
  364. NOH JY, Cheong HJ, Kim WJ, Choi JY, et al
    Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination: Running title: Optimal vaccination interval and ceiling effect.
    J Infect. 2022 Jul 31. pii: S0163-4453(22)00456.
    >> Share

  365. BOJKOVA D, Stack R, Rothenburger T, Kandler JD, et al
    Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.
    J Infect. 2022 Jul 30. pii: S0163-4453(22)00455.
    >> Share

  366. MURPHY SL, Halvorsen B, Barratt-Due A, Am DR, et al
    Remdesivir modifies interferon response in hospitalized COVID-19 patients.
    J Infect. 2022 Jul 29. pii: S0163-4453(22)00450.
    >> Share

  367. DZINAMARIRA T, Moyo E, Moyo P, Pierre G, et al
    Childhood immunization services accessibility and utilization during the COVID-19 pandemic in Africa.
    J Infect. 2022 Jul 29. pii: S0163-4453(22)00445.
    >> Share

  368. PASCARELLA S, Ciccozzi M, Benvenuto D, Borsetti A, et al
    Peculiar Variations of the Electrostatic Potential of Spike Protein N-terminal Domain Associated with the Emergence of Successive SARS-CoV-2 Omicron Lineages.
    J Infect. 2022 Jul 28. pii: S0163-4453(22)00426.
    >> Share

  369. LINA L, Fangfang Z, Sevalie S, Dawei Z, et al
    Characteristics of SARS-CoV-2 exhaled by COVID-19 patients.
    J Infect. 2022 Jul 28. pii: S0163-4453(22)00424.
    >> Share

  370. FU J, Luo Y, Fang X, Lu J, et al
    Genetic variation of Golgi membrane protein 1 is associated with COVID-19 disease.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00420.
    >> Share

  371. VELLAS C, Kamar N, Izopet J
    Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00422.
    >> Share

  372. LI M, Luo Q, Gong C, Li AH, et al
    Prospective Surveillance of Human Adenovirus in Acute Respiratory Infections Reveals Epidemiological Features and the Disappearance of Species B During the COVID-19 Pandemic in Beijing, China.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00423.
    >> Share

  373. HUANG L
    Adjusted control rate closely associated with the epidemiologic evolution of the recent COVID-19 wave in Shanghai, with 94.3% of all new cases being asymptomatic on first diagnosis.
    J Infect. 2022 Jul 14. pii: S0163-4453(22)00418.
    >> Share

  374. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.
    >> Share

  375. KHANNA R, Htun HL, Lianjie AL, Kyaw WM, et al
    Staff and patient surveillance in hospitals: good sentinels for the emergence of new SARS-CoV-2 variants.
    J Infect. 2022 Jul 7. pii: S0163-4453(22)00411.
    >> Share

  376. VERA-LISE I, Dominik E, Elisabeth R, Kerstin H, et al
    "Rapid reinfections with different or same Omicron SARS-CoV-2 sub-variants".
    J Infect. 2022 Jul 7. pii: S0163-4453(22)00412.
    >> Share

  377. LI M, Yu T
    Statistical concern on evaluating the consistency between gargle samples and nasopharyngeal (NP) swabs in RT-qPCR-based mass screening approach for the diagnosis of COVID-19.
    J Infect. 2022 Jul 6. pii: S0163-4453(22)00408.
    >> Share

  378. MARTIN-BLONDEL G, Marcelin AG, Soulie C, Kaisaridi S, et al
    Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00406.
    >> Share

  379. YAN Y, Davgadorj C, Lyu C, Zhang S, et al
    Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00407.
    >> Share

  380. GAO X, Zhang S, Gou J, Wen Y, et al
    Spike-mediated ACE2 down-regulation involved in the pathogenesis of SARS-CoV-2 infection.
    J Infect. 2022 Jul 3. pii: S0163-4453(22)00404.
    >> Share

  381. YUAN W, Hou Y, Lin Q, Chen L, et al
    How China responds to Omicron.
    J Infect. 2022;85:90-122.
    >> Share

  382. YANG M, Li A, Wang Y, Tran C, et al
    Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis.
    J Infect. 2022 Jul 1. pii: S0163-4453(22)00384.
    >> Share

    June 2022
  383. CARBONELL R, Urgeles S, Salgado M, Rodriguez A, et al
    NEGATIVE PREDICTIVE VALUE OF PROCALCITONIN TO RULE OUT BACTERIAL RESPIRATORY CO-INFECTION IN CRITICAL COVID-19 PATIENTS.
    J Infect. 2022 Jun 30. pii: S0163-4453(22)00380.
    >> Share

  384. SACERDOTE C, Milani L, Castiglione A, Pagano E, et al
    Risk of Intensive Care Unit admission or mortality in patients hospitalised for COVID-19 during the first two waves: an Italian cohort study.
    J Infect. 2022 Jun 30. pii: S0163-4453(22)00379.
    >> Share

  385. O'MORAIN N, Stack R, Doherty J, Tosetto M, et al
    Research Letter: Faecal calprotectin as a potential biomarker of disease severity in SARS-CoV-2 infection.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00372.
    >> Share

  386. REN Y, Liu Y, Zhang Z, Liu Y, et al
    SNX27-mediated endocytic recycling of GLUT1 is suppressed by SARS-CoV-2 spike, possibly explaining neuromuscular disorders in patients with COVID-19.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00377.
    >> Share

  387. FOURGEAUD J, Toubiana J, Chappuy H, Delacourt C, et al
    No durable impact of COVID-19 measures on the hospital burden of Respiratory Syncytial Virus (France, 2018-2022).
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00375.
    >> Share

  388. YIN Y, Li X, Qian C, Cheng B, et al
    Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00374.
    >> Share

  389. YANG M, Li A, Jiang L, Wang Y, et al
    Regdanvimab improves disease mortality and morbidity in patients with COVID-19: a meta-analysis.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00369.
    >> Share

  390. NIYOMNAITHAM S, Toh ZQ, Licciardi PV, Wongprompitak P, et al
    Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00370.
    >> Share

  391. RICHARDS A, Muddassir M, Sampson F, MacLachlan L, et al
    Evaluation of pre-hospital COVID-19 rapid antigen tests by paramedics and their use in a direct admission pathway: Pre-Hospital COVID-19 rapid antigen tests.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00371.
    >> Share

  392. PENG H, Wu X, Xiong S, Li C, et al
    Gout and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization analysis.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00366.
    >> Share

  393. HATCHER J, Gil E, Storey N, Brown JR, et al
    Reactivation/relapse of SARS-CoV-2 in a child following haematopoietic stem cell transplantation, confirmed by whole genome sequencing, following apparent viral clearance.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00367.
    >> Share

  394. COCHINO AV, Farkas OM, Ioan A
    Pediatric Patients with Immune-Mediated Diseases on Immunosuppressants Have Low Risk of Severe COVID-19 and No Increase in Flare Rate after SARS CoV-2 Exposure.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00365.
    >> Share

  395. COULSON JM, Adams A, Gray LA, Evans A, et al
    COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00363.
    >> Share

  396. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    >> Share

  397. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.
    >> Share

  398. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.
    >> Share

  399. GABBI C, Renieri A, Strandvik B
    Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries.
    J Infect. 2022 Jun 11. pii: S0163-4453(22)00359.
    >> Share

  400. SANG L, Cheng B, Yu Y, Xi Y, et al
    The efficacy and safety of IBI314 on Delta and Omicron variant of SARS-CoV-2: first-in-human evidence.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00354.
    >> Share

  401. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.
    >> Share

  402. LV P, Hu B, Hua R, Zhang J, et al
    A novelly designed protein antagonist confers potent neutralization against SARS-COV-2 variants of concern.
    J Infect. 2022 Jun 3. pii: S0163-4453(22)00350.
    >> Share

  403. IJAZ S, Dicks S, Jegatheesan K, Parker E, et al
    Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: antibody dynamics and linkage to severity of COVID-19 in hospital inpatients.
    J Infect. 2022 Jun 3. pii: S0163-4453(22)00339.
    >> Share

  404. ABDI B, Ndoadoumgue AL, Djebara S, Zafilaza K, et al
    High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients.
    J Infect. 2022 Jun 2. pii: S0163-4453(22)00346.
    >> Share

  405. MELLON G, Rouquette A, Fac C, Carton B, et al
    SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study.
    J Infect. 2022 Jun 2. pii: S0163-4453(22)00345.
    >> Share

  406. GUO Z, Zhao S, Ryu S, Mok CKP, et al
    Superspreading potential of infection seeded by the SARS-CoV-2 Omicron BA.1 variant in South Korea.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00344.
    >> Share

  407. ZHANG Y, Li J, Jiang L, Chen Q, et al
    Comparison of SARS-CoV-2 aerosol emission from patients with Omicron BA.1 or BA.2 subvariant infection.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00342.
    >> Share

  408. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    EVALUATING THE POTENTIAL IMPACT OF COVID-19 PASSPORTS IN LITHUANIA.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00340.
    >> Share

  409. LI Y, Guo Y, Duan Y
    Changes in Streptococcus pneumoniae infection in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00348.
    >> Share

    May 2022
  410. WANG B, Fu J, Lu A, Yang J, et al
    Suitability assessment of CD24 targeted-therapy in the cancer patients with COVID-19: Preliminary results from pan-cancer.
    J Infect. 2022 May 31. pii: S0163-4453(22)00337.
    >> Share

  411. GIANNONE D, Vecchione MB, Czernikier A, Polo ML, et al
    SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV.
    J Infect. 2022 May 27. pii: S0163-4453(22)00315.
    >> Share

  412. KAMALI Z, Vonk JM, Thio CHL, Vaez A, et al
    A Mendelian randomization cytokine screen reveals IL-13 as causal factor in risk of severe COVID-19.
    J Infect. 2022 May 23. pii: S0163-4453(22)00313.
    >> Share

  413. SA R, Isidro J, Borges V, Duarte S, et al
    Unravelling the hurdles of a large COVID-19 epidemiological investigation by viral genomics.
    J Infect. 2022 May 21. pii: S0163-4453(22)00302.
    >> Share

  414. SOVIK S, Barrat-Due A, Kasine T, Olasveengen T, et al
    Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation.
    J Infect. 2022 May 20. pii: S0163-4453(22)00305.
    >> Share

  415. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.
    >> Share

  416. LIU L, Fan X, Guan Q, Yu C, et al
    Bioavailable testosterone level is associated with COVID-19 severity in female: A sex-stratified Mendelian randomization study.
    J Infect. 2022 May 13. pii: S0163-4453(22)00287.
    >> Share

  417. WU X, Peng H, Xiong S, Li C, et al
    Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer: COVID-19 infection, severity and risk of endometrial cancer.
    J Infect. 2022 May 10. pii: S0163-4453(22)00261.
    >> Share

  418. VAN GRONINGEN KM, Dao BL, Gounder P
    Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.
    J Infect. 2022 May 9. pii: S0163-4453(22)00259.
    >> Share

  419. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.
    >> Share

  420. LUCIJANIC M, Cikara T, Bistrovic P, Papic I, et al
    Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis.
    J Infect. 2022 May 2. pii: S0163-4453(22)00251.
    >> Share

  421. WAN Z, Lu R, Zhao Y, Zhang C, et al
    Diagnostic strategy of SARS-CoV-2 for containment under China's zero-COVID-19 policy.
    J Infect. 2022 May 1. pii: S0163-4453(22)00250.
    >> Share

  422. FERNANDEZ-DE-LAS-PENAS C, Martin-Guerrero JD, Cancela-Cilleruelo I, Moro-Lopez-Menchero P, et al
    Exploring the recovery curves for long-term post-COVID functional limitations on daily living activities: The LONG-COVID-EXP-CM multicenter study.
    J Infect. 2022;84:722-746.
    >> Share

  423. MARIANI C, Borgonovo F, Capetti AF, Oreni L, et al
    Persistence of Long-COVID symptoms in a heterogenous prospective cohort.
    J Infect. 2022;84:722-746.
    >> Share

    April 2022
  424. HIROTSU Y, Maejima M, Shibusawa M, Natori Y, et al
    SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from September 2021 to March 2022.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00247.
    >> Share

  425. GIANNITRAPANI L, Augello G, Mirarchi L, Amodeo S, et al
    Outcome predictors in SARS-CoV-2 disease (COVID-19): the prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00245.
    >> Share

  426. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    >> Share

  427. LI A, Zhang L
    Reduced incidence of acute pharyngitis and increased incidence of chornic pharyngitis under COVID-19 control strategy in Beijing.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00249.
    >> Share

  428. RANA MS, Usman MM, Ikram A, Salman M, et al
    The negative impact of the COVID-19 Pandemic on immunization and the positive impact on Polio eradication in Pakistan and Afghanistan. A dismal scenario.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00246.
    >> Share

  429. YUAN S, Jiang SC, Zhang ZW, Fu YF, et al
    Surface electrostatic shift on spike protein decreased antibody activities against SARS-CoV-2 Omicron variant.
    J Infect. 2022 Apr 23. pii: S0163-4453(22)00215.
    >> Share

  430. NGUYEN NN, Houhamdi L, Hoang VT, Stoupan D, et al
    High rate of reinfection with the SARS-CoV-2 Omicron variant.
    J Infect. 2022 Apr 23. pii: S0163-4453(22)00216.
    >> Share

  431. HE L, Zeng C, Xu W, Li Y, et al
    Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00214.
    >> Share

  432. AO G, Li A, Wang Y, Tran C, et al
    Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00210.
    >> Share

  433. CIUFFREDA L, Alcoba-Florez J, Lorenzo-Salazar JM, Gil-Campesino H, et al
    Association of the Delta SARS-CoV-2 variant with 28-day hospital mortality between December 2020 and September 2021.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00212.
    >> Share

  434. LI Y, Wei L, He L, Sun J, et al
    Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00208.
    >> Share

  435. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Reduced neutralizing antibody response in naive Covishield vaccinees against Omicron emphasizes booster vaccination.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00213.
    >> Share

  436. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.
    >> Share

  437. CAI J, Hu S, Lin Q, Ren T, et al
    China's 'dynamic zero COVID-19 strategy' will face greater challenges in the future.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00209.
    >> Share

  438. DAVIES J, Gibani MM, Portone G, McGregor A, et al
    Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection.
    J Infect. 2022 Apr 12. pii: S0163-4453(22)00202.
    >> Share

  439. REN Y, Lv L, Li P, Zhang L, et al
    Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction.
    J Infect. 2022 Apr 11. pii: S0163-4453(22)00201.
    >> Share

  440. ZSIGMOND B, Breathnach AS, Mensah A, Ladhani SN, et al
    Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England".
    J Infect. 2022 Apr 10. pii: S0163-4453(22)00203.
    >> Share

  441. WHITAKER H, Tsang RS, Button E, Andrews N, et al
    Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00198.
    >> Share

  442. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    >> Share

  443. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.
    >> Share

  444. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.
    >> Share

  445. MARTIN-BLONDEL G, Marcelin AG, Soulie C, Kaisaridi S, et al
    Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S CoCoPrev study).
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00196.
    >> Share

  446. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.
    >> Share

  447. BADDAL B, Bostanci A
    The impact of COVID-19 on the molecular epidemiology of seasonal viral respiratory infections, Cyprus.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00192.
    >> Share

  448. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.
    >> Share

  449. AKBAR S, Pan D, Ehdode A, Islam R, et al
    Prognostic value of maximum NEWS-2 scores in addition to ISARIC 4C scores for patients admitted to hospital with COVID-19.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00195.
    >> Share

  450. ONG JY, Wang CH, Ms YT, Chen FL, et al
    Nosocomial septicemia in COVID-19 Nosocomial K. pneumoniae, A. baumannii, and Elizabethkingia meningoseptica Septicemia in a Patient of COVID-19.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00188.
    >> Share

  451. SONG W, Yang Y, Huang Y, Chen L, et al
    Acute respiratory infections in children, before and after the COVID-19 pandemic, a sentinel study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00183.
    >> Share

  452. GAGNAIRE J, Bonjean P, Verot E, Boulamail B, et al
    SARS-CoV-2 rapid test versus RT-qPCR on noninvasive respiratory self-samples during a city mass testing campaign.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00184.
    >> Share

  453. BAEK YJ, Lee YJ, Kim JI, Lee S, et al
    Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: a retrospective cohort study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00186.
    >> Share

  454. DUVERGER C, Monteil C, Souyri V, Md SF, et al
    Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.
    J Infect. 2022 Apr 1. pii: S0163-4453(22)00179.
    >> Share

    March 2022
  455. YOON JG, Yoo JS, Lee J, Hyun HJ, et al
    Viable SARS-CoV-2 Shedding Under Remdesivir and Dexamethasone Treatment.
    J Infect. 2022 Mar 26. pii: S0163-4453(22)00177.
    >> Share

  456. MENG J, Ge Q, Li J, Lu X, et al
    Protective trend of anti-androgen therapy during the COVID-19 pandemic: a meta-analysis.
    J Infect. 2022 Mar 24. pii: S0163-4453(22)00175.
    >> Share

  457. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.
    >> Share

  458. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.
    >> Share

  459. YANG G, Ren Z, Zou Y, Xu Q, et al
    Antimicrobial stewardship in non-COVID-19 patients with fever and respiratory symptoms in outpatient settings: lessons from the "dynamic zero-COVID policy" in mainland China.
    J Infect. 2022 Mar 18. pii: S0163-4453(22)00141.
    >> Share

  460. MURGIA F, Fiamma M, Serra S, Olla S, et al
    The impact of secondary infections in COVID-19 critically ill patients.
    J Infect. 2022 Mar 18. pii: S0163-4453(22)00171.
    >> Share

  461. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.
    >> Share

  462. RYAN P, Perez-Garcia F, Torres-Macho J, Bibiano C, et al
    Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021.
    J Infect. 2022 Mar 16. pii: S0163-4453(22)00139.
    >> Share

  463. AO G, Wang Y, Li A, Tran C, et al
    The effect of canakinumab on clinical outcomes in patients with COVID-19: a meta-analysis.
    J Infect. 2022 Mar 14. pii: S0163-4453(22)00137.
    >> Share

  464. CHEN C, Tang J, Wang C, Wen W, et al
    Meta-Analysis of Post-traumatic Stress Disorder and COVID-19 in Patients Discharged.
    J Infect. 2022 Mar 10. pii: S0163-4453(22)00134.
    >> Share

  465. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.
    >> Share

  466. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.
    >> Share

  467. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.
    >> Share

  468. FANTINI J, Devaux CA, Yahi N, Frutos R, et al
    The novel hamster-adapted SARS-CoV-2 Delta variant may be selectively advantaged in humans.
    J Infect. 2022 Mar 6. pii: S0163-4453(22)00129.
    >> Share

  469. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.
    >> Share

  470. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    >> Share

  471. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.
    >> Share

  472. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.
    >> Share

  473. HAO M, Zhu Y, Fan S, Wu X, et al
    Detection of human respiratory viruses among hospitalized children aged
    J Infect. 2022;84:418-467.
    >> Share

    February 2022
  474. PUTRI DU, Lin CF, Hung CS, Huang CK, et al
    Distinct B and NKT cell Responses Shape the Delayed Response to ChAdOx1 nCoV-19 Vaccine in End-Stage Renal Disease.
    J Infect. 2022 Feb 28. pii: S0163-4453(22)00116.
    >> Share

  475. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.
    >> Share

  476. KONIG S, Hohenstein S, Leiner J, Hindricks G, et al
    National mortality data for Germany before and throughout the pandemic: there is an excess mortality exceeding COVID-19-attributed fatalities.
    J Infect. 2022 Feb 26. pii: S0163-4453(22)00113.
    >> Share

  477. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load.
    J Infect. 2022 Feb 26. pii: S0163-4453(22)00114.
    >> Share

  478. PASCARELLA S, Ciccozzi M, Bianchi M, Benvenuto D, et al
    The value of electrostatic potentials of the Spike Receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 Variants. of Concern.
    J Infect. 2022 Feb 23. pii: S0163-4453(22)00112.
    >> Share

  479. DE MICHELENA P, Torres I, Ramos-Garcia A, Gozalbes V, et al
    Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant.
    J Infect. 2022 Feb 22. pii: S0163-4453(22)00110.
    >> Share

  480. FERRI S, Polidoro A, Ciacciarelli M, Ceratti U, et al
    Decline of immune humoral response after BNT162b2 Vaccine.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00076.
    >> Share

  481. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016